Embrace the future of trademark practice with our AI-powered solution, providing a transformative approach to both trademark prosecution and litigation.
Maximize your brand's impact with AI-powered solutions for brand content creation, management and protection. (Invite only to pilot clients)
Like a Google reverse image search and text search, but for trademarks. Search for existing marks in USPTO...
Catch potential conflicts as soon as they’re filed. Everything you need in one place.
Discover threats to your clients’ trademarks from over 60 million eCommerce listings.
Most advanced image recognition for trademark law
Case research has never been easier thanks to the largest knowledge graph in trademark law
For the first time, trademark lawyers and professionals have their own “achievement profiles”
Reconsidering portfolio management as revenue management
Hear what your peers love about Huski.ai for their trademark practices.
Browse potential refusal cases in pending applications against existing marks
Browse new trademark applications everyday. Discover business trends
The only ranking in the industry that is based on big data analysis of attorneys’ performance on trademark applications and litigations
The only ranking in the industry that is based on big data analysis of brand litigation records and brand impact factor
Your source of data insights, technology progress, and industry trend of trademark law.
We are AI engineers and intellectual property litigation professionals. As innovators ourselves, we believe that creativity and innovation are what drive us forward, and we want all individuals, professionals, and businesses of all sizes enjoy and benefit from the process of innovation.
Huski.ai exists to make brand creation and protection easy with cutting-edge AI.
Built by AI experts in Silicon Valley who worked on self-driving cars and other cutting-edge tech innovations, Huski.ai is developing unprecedented technologies for trademark prosecution and protection, ultimately transforming trademark and brand protection for all.
We deeply appreciate the media's recognition about our work. It's a great motivation to keep us moving forward.
U.S Class(es): 005, 006, 018, 044, 046, 051, 052
Class Status: Active
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; pharmaceutical anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy preparations for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.;